155 related articles for article (PubMed ID: 34537675)
21. Therapy response and prognosis of patients with early breast cancer with low positivity for hormone receptors - An analysis of 2765 patients from neoadjuvant clinical trials.
Villegas SL; Nekljudova V; Pfarr N; Engel J; Untch M; Schrodi S; Holms F; Ulmer HU; Fasching PA; Weber KE; Albig C; Heinrichs C; Marmé F; Hartmann A; Hanusch C; Schmitt WD; Huober J; Lederer B; van Mackelenbergh M; Tesch H; Jackisch C; Rezai M; Sinn P; Sinn BV; Hackmann J; Kiechle M; Schneeweiss A; Weichert W; Denkert C; Loibl S
Eur J Cancer; 2021 May; 148():159-170. PubMed ID: 33743484
[TBL] [Abstract][Full Text] [Related]
22. A prognostic model based on combining estrogen receptor expression and Ki-67 value after neoadjuvant chemotherapy predicts clinical outcome in locally advanced breast cancer: extension and analysis of a previously reported cohort of patients.
Miglietta L; Morabito F; Provinciali N; Canobbio L; Meszaros P; Naso C; Murialdo R; Boitano M; Salvi S; Ferrarini M
Eur J Surg Oncol; 2013 Oct; 39(10):1046-52. PubMed ID: 23890870
[TBL] [Abstract][Full Text] [Related]
23. Long-term treatment efficacy in primary inflammatory breast cancer by hormonal receptor- and HER2-defined subtypes.
Masuda H; Brewer TM; Liu DD; Iwamoto T; Shen Y; Hsu L; Willey JS; Gonzalez-Angulo AM; Chavez-MacGregor M; Fouad TM; Woodward WA; Reuben JM; Valero V; Alvarez RH; Hortobagyi GN; Ueno NT
Ann Oncol; 2014 Feb; 25(2):384-91. PubMed ID: 24351399
[TBL] [Abstract][Full Text] [Related]
24. Association of TILs with clinical parameters, Recurrence Score® results, and prognosis in patients with early HER2-negative breast cancer (BC)-a translational analysis of the prospective WSG PlanB trial.
Kolberg-Liedtke C; Gluz O; Heinisch F; Feuerhake F; Kreipe H; Clemens M; Nuding B; Malter W; Reimer T; Wuerstlein R; Graeser M; Shak S; Nitz U; Kates R; Christgen M; Harbeck N
Breast Cancer Res; 2020 May; 22(1):47. PubMed ID: 32408905
[TBL] [Abstract][Full Text] [Related]
25. Ki67 Changes Identify Worse Outcomes in Residual Breast Cancer Tumors After Neoadjuvant Chemotherapy.
Cabrera-Galeana P; Muñoz-Montaño W; Lara-Medina F; Alvarado-Miranda A; Pérez-Sánchez V; Villarreal-Garza C; Quintero RM; Porras-Reyes F; Bargallo-Rocha E; Del Carmen I; Mohar A; Arrieta O
Oncologist; 2018 Jun; 23(6):670-678. PubMed ID: 29490940
[TBL] [Abstract][Full Text] [Related]
26. [Clinical Significance of the Curative Effect after Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer-Correlation to Prognosis].
Haku E; Kojima Y; Sakamaki K; Kitajima M; Takishita M; Sakamoto N; Tazou M; Nakano M; Kuroda T; Yoshie R; Tsuruga T; Shimo A; Shimo A; Motoyoshi A; Kawamoto H; Fukuda M; Tsugawa K
Gan To Kagaku Ryoho; 2020 Oct; 47(10):1449-1455. PubMed ID: 33130739
[TBL] [Abstract][Full Text] [Related]
27. Prognostic significance of residual nodal burden using lymph node ratio in locally advanced breast cancer after neoadjuvant chemotherapy.
Agarwal R; Philip A; Pavithran K; Rajanbabu A; Goel G; Vijaykumar DK
Indian J Cancer; 2019; 56(3):228-235. PubMed ID: 31389386
[TBL] [Abstract][Full Text] [Related]
28. Predictive value of tumor-infiltrating lymphocytes for response to neoadjuvant chemotherapy and breast cancer prognosis.
Li X; Tan Q; Li H; Yang X
J Surg Oncol; 2021 Jan; 123(1):89-95. PubMed ID: 33047336
[TBL] [Abstract][Full Text] [Related]
29. Pathologic response and residual tumor cellularity after neo-adjuvant chemotherapy predict prognosis in breast cancer patients.
Gentile D; Sagona A; De Carlo C; Fernandes B; Barbieri E; Di Maria Grimaldi S; Jacobs F; Vatteroni G; Scardina L; Biondi E; Vinci V; Trimboli RM; Bernardi D; Tinterri C
Breast; 2023 Jun; 69():323-329. PubMed ID: 37001289
[TBL] [Abstract][Full Text] [Related]
30. Comparison of Pathologic Response Evaluation Systems after Anthracycline with/without Taxane-Based Neoadjuvant Chemotherapy among Different Subtypes of Breast Cancers.
Lee HJ; Park IA; Song IH; Kim SB; Jung KH; Ahn JH; Ahn SH; Kim HH; Gong G
PLoS One; 2015; 10(9):e0137885. PubMed ID: 26394326
[TBL] [Abstract][Full Text] [Related]
31. Impact of the Histologic Pattern of Residual Tumor After Neoadjuvant Chemotherapy on Recurrence and Survival in Stage I-III Breast Cancer.
Laws A; Pastorello R; Dey T; Grossmith S; King C; McGrath M; Schnitt SJ; Mittendorf EA; King T
Ann Surg Oncol; 2022 Nov; 29(12):7726-7736. PubMed ID: 35810224
[TBL] [Abstract][Full Text] [Related]
32. Residual proliferative cancer burden to predict long-term outcome following neoadjuvant chemotherapy.
Sheri A; Smith IE; Johnston SR; A'Hern R; Nerurkar A; Jones RL; Hills M; Detre S; Pinder SE; Symmans WF; Dowsett M
Ann Oncol; 2015 Jan; 26(1):75-80. PubMed ID: 25361988
[TBL] [Abstract][Full Text] [Related]
33. Prognostic Factors in HER2-Positive Primary Breast Cancer Patients Treated Using Neoadjuvant Chemotherapy Plus Trastuzumab.
Fujita N; Enomoto Y; Inakami K; Yanagisawa T; Iguchi C; Aono T; Nomura T; Yamamoto H; Kasugai T; Shiba E
Oncology; 2020; 98(1):35-41. PubMed ID: 31574500
[TBL] [Abstract][Full Text] [Related]
34. Assessment of residual cancer burden and survival in neoadjuvant chemotherapy of inoperable stage III breast cancer: A ten-year follow-up analysis in Vietnam.
Pham HK; Le TD; Nguyen TP; Le TU; Ta HH; Nguyen VC
Pathol Res Pract; 2024 Feb; 254():155099. PubMed ID: 38244433
[TBL] [Abstract][Full Text] [Related]
35. Response and survival of breast cancer intrinsic subtypes following multi-agent neoadjuvant chemotherapy.
Prat A; Fan C; Fernández A; Hoadley KA; Martinello R; Vidal M; Viladot M; Pineda E; Arance A; Muñoz M; Paré L; Cheang MC; Adamo B; Perou CM
BMC Med; 2015 Dec; 13():303. PubMed ID: 26684470
[TBL] [Abstract][Full Text] [Related]
36. Expression of Cyclin D1 protein in residual tumor after neoadjuvant chemotherapy for breast cancer.
Villegas SL; Darb-Esfahani S; von Minckwitz G; Huober J; Weber K; Marmé F; Furlanetto J; Schem C; Pfitzner BM; Lederer B; Engels K; Kümmel S; Müller V; Mehta K; Denkert C; Loibl S
Breast Cancer Res Treat; 2018 Feb; 168(1):179-187. PubMed ID: 29177689
[TBL] [Abstract][Full Text] [Related]
37. Establishment and external validation of a prognostic model for predicting disease-free survival and risk stratification in breast cancer patients treated with neoadjuvant chemotherapy.
Lai J; Wang H; Peng J; Chen P; Pan Z
Cancer Manag Res; 2018; 10():2347-2356. PubMed ID: 30122984
[TBL] [Abstract][Full Text] [Related]
38. Residual cancer burden index and tumor-infiltrating lymphocyte subtypes in triple-negative breast cancer after neoadjuvant chemotherapy.
Pinard C; Debled M; Ben Rejeb H; Velasco V; Tunon de Lara C; Hoppe S; Richard E; Brouste V; Bonnefoi H; MacGrogan G
Breast Cancer Res Treat; 2020 Jan; 179(1):11-23. PubMed ID: 31529299
[TBL] [Abstract][Full Text] [Related]
39. Prediction of Treatment Response to Neoadjuvant Chemotherapy in Breast Cancer by Subtype Using Tumor-infiltrating Lymphocytes.
Asano Y; Kashiwagi S; Goto W; Takada K; Takahashi K; Hatano T; Takashima T; Tomita S; Motomura H; Ohsawa M; Hirakawa K; Ohira M
Anticancer Res; 2018 Apr; 38(4):2311-2321. PubMed ID: 29599354
[TBL] [Abstract][Full Text] [Related]
40. A nomogram for predicting locoregional recurrence in primary breast cancer patients who received breast-conserving surgery after neoadjuvant chemotherapy.
Matsuda N; Hayashi N; Ohde S; Yagata H; Kajiura Y; Yoshida A; Suzuki K; Nakamura S; Tsunoda H; Yamauchi H
J Surg Oncol; 2014 Jun; 109(8):764-9. PubMed ID: 24647874
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
